The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is a formal academic unit within the Division of the Biological Sciences (BSD), and the main body within the University to plan, facilitate, and promote research, education, community outreach, and health information services all focused on cancer, as well as cancer-related fundraising. UCCCC Administration is responsible for operationalizing and monitoring these activities. The Associate Director (AD) for Administration, Marcy List, PhD, has the status of Departmental Executive Administrator and attends all BSD-level and University of Chicago Medicine (UCM) Operations meetings, thereby representing the UCCCC interests at the institutional level. Under the leadership of Dr. List, the UCCCC Administrative Core is responsible for oversight and management of activities that support the mission of the Center and the research of its members including, but not limited to, management of Center finances, personnel, grants and contracts, purchasing, and philanthropy; oversight of space utilization; facilitation of recruitment efforts; oversight of Shared Resources; Pilot Project and Team Science Award solicitation, review and funds allocation; coordination of Center meetings and facilitation of Working Groups and inter-and intraprogrammatic interactions; communications with UCCCC members, the lay public, donors and other Cancer Centers; and coordination of strategic planning and evaluation efforts for the Center. The Administrative Core includes: Finances and Human Resources (HR) (Business Manager and 3 FTEs) responsible for management of $8 million in peer-reviewed funding and $13.4 million in philanthropy, and HR issues for 44 UCCCC employees; Information Technology (Director and 5 FTEs) responsible for all informatics and database support for UCCCC administrative groups, the Cancer Clinical Trials Office (CCTO), coordination of UCCCC IT activities with those of the BSD and UCM, and management of the UCCCC website; and Grant Support and General Office Support (3 FTEs) responsible for all non-financial pre- and post-award for multi-investigator grants, and general program development support (e.g., planning and evaluation, membership, recruitment, seminars). Key accomplishments of the Administrative Core over the current grant period include: development of a new membership database, design of a new website, increased collaborations with both internal and external partners, submission of 36 peer-reviewed grants/supplements, significant expansion of our educational and community outreach initiatives, and administrative/implementation of the launch of a large cohort study, Chicago Multiethnic Prevention and Surveillance Study (COMPASS). We have successfully set up clinical trials infrastructure at the UCCCC at Silver Cross Hospital as well as integrating them into our communications and marketing efforts. Over the next grant period, we will build on these efforts to further enhance our informatics infrastructure for both administrative and clinical research both at UCM as well as at new community sites (e.g., Orland Park) and affiliates (Ingalls Hospital). For Year 43, the Center requests $259,736, approximately 8.5% of the CCSG. Income Source Current Support Current Percent Proposed Support (Yr 1) Proposed Percent (Yr 1) CCSG $216,565 14% $259,736 15% CCSG supplements $71,203 4% $0 0% Institutional support $1,230,410 77% $1,387,322 80% Peer-reviewed grants & contracts $74,144 5% $76,368 4% *Total Operating Budget $1,592,322 100% $1,723,427 100% * Includes Finance Group, Grant Support and General Office Support, IT Group; excludes Communications Group, CCTO, and Office of Community Engagement and Cancer Disparities (OCECD) staff.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-43
Application #
9489788
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-22
Budget End
2019-03-31
Support Year
43
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications